-
公开(公告)号：US10739356B2
公开(公告)日：2020-08-11
申请号：US15742484
申请日：2016-07-08
申请人： CHU DE NICE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS , UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS
摘要： Disclosed is a method for assessing the prognosis of idiopathic membranous nephropathy in a body fluid sample from a human subject, based on profiling PLA2R1 epitopes recognized by autoantibodies in the sample. The method further relates to analysis of PLA2R1 epitope spreading amongst three PLA2R1 domains (Cys R, CTLD1 and CTLD7) that are recognized by anti-PLA2R1 autoantibodies, two of which (CTLD1 and CTLD7) are more closely associated with active idiopathic membranous nephropathy and likely linked by a mechanism of epitope spreading.
-
2.发明申请公开(公告)号：US20180203020A1
公开(公告)日：2018-07-19
申请号：US15742484
申请日：2016-07-08
申请人： CHU DE NICE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNR , UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6878 , G01N2333/705 , G01N2800/347 , G01N2800/52
摘要： The invention relates to a method for assessing the prognosis of idiopathic membranous nephropathy in a subject, based on the analysis of PLA2R1 epitope profile. The invention further relates to a method for monitoring the progression of idiopathic membranous nephropathy based on the analysis of the PLA2R1 epitope spreading. The invention highlights that three PLA2R1 domains (Cys R, CTLD1 and CTLD7) are involved in anti-PLA2R1 activity, with two of them (CTLD1 and CTLD7) more closely associated with active idiopathic membranous nephropathy and likely linked by a mechanism of epitope spreading.
-
搜索结果
2 条记录 (耗时 0.023 秒)
